Treatment
Fludarabine clinical trials
We’re tracking 301 recruiting studies that include Fludarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT05508009RecruitingPhase 1/Phase 2
Kidney transplant with donor-matched stem cell treatment
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Palo Alto, CaliforniaAges 1–30 - NCT05981014RecruitingPhase 1/Phase 2
Immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether taking immune cells from your lymph nodes and giving them back to you can help shrink breast cancer that has not responded fully to initial chemotherapy. It is for women with HER2-negative breast cancer who have had stable disease after two cycles of a standard chemotherapy combination.
Guangzhou, GuangdongAges 18–70 - NCT05981001RecruitingPhase 1/Phase 2
Experimental cell therapy for advanced HER2-negative breast cancer
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Guangzhou, GuangdongAges 18–70 - NCT06121570RecruitingPhase 1
Study of immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06121557RecruitingPhase 1
Immune cells from lymph nodes for advanced HER2-negative breast cancer
This trial tests a treatment using your own immune cells taken from lymph nodes near the tumor. The cells are grown in a lab and given back to you to fight cancer, along with another drug chosen by your doctor.
Guangzhou, GuangdongAges 18–70 - NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT06336395RecruitingPhase 2
ALL treatment study for people under 41
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
Kuala LumpurAges Up to 40 years - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT05693844RecruitingPhase 1/Phase 2
MSLN CAR T cell therapy for advanced solid tumors
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Beijing, Beijing MunicipalityAges 18–75 - NCT07838714RecruitingPhase 1
Cord blood CAR-T cells for relapsed B-cell leukemia
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07830342RecruitingPhase 1
Study of tumor-infiltrating lymphocyte therapy for advanced non-small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
ShanghaiAges 18–75 - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT07770802RecruitingPhase 1
Study of an investigational cell therapy for advanced kidney cancer
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
BeijingAges 18–75 - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT06581562RecruitingPhase 1
Testing rituximab plus AB-101 for autoimmune diseases
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Plantation, FloridaAges 18 years+ - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07672483RecruitingPhase 1
Gene therapy for solid tumors that returned after treatment
This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07676877RecruitingPhase 1
Low-dose radiation before CAR-T therapy for large B-cell lymphoma
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Columbus, OhioAges 18 years+ - NCT06530303RecruitingPhase 1/Phase 2
Personalized immune cell therapy for colorectal cancer
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT06640582RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced brain cancer
This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.
Beijing, Beijing MunicipalityAges 16–90
Common questions
- Are there clinical trials studying Fludarabine?
- Yes. Clin2 currently lists 301 recruiting studies that include Fludarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fludarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fludarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fludarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.